IP Library Granted Patent US 7,589,178
Granted Patent B2
US 7,589,178 · App. 10/492,191 · Granted Sep 15, 2009

Thrombin-cleavable chimeric proteins

Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,589,178
App. No.
10/492,191
Granted
Sep 15, 2009
Kind
B2
Abstract

The invention relates to chimeric proteins comprising an artificial sequence for cleavage by thrombin, in which the activation peptide is fibrinopeptide A. Preferably, said chimeric proteins are derived from the zymogen of a serine protease such as PC or FX, by replacing the activation peptide of said zymogen with fibrinopeptide A, or a portion thereof, comprising at least amino acids P 10 to P 1 of said fibrinopeptide.

Claims (24)

1. A chimeric thrombin-cleavable derivative of a serine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a native cleavage site for thrombin of the protein C, wherein the amino acids P 1 ′-P 2 ′-P 3 ′ are represented by Leu-Ile-Asp, or the factor X, wherein the amino acids P 1 ′-P 2 ′-P 3 ′ are represented by Ile-Val-Gly.

2. An isolated nucleic acid molecule encoding the chimeric protein according to claim 1 .

3. A recombinant vector, comprising the nucleic acid molecule according to claim 2 .

4. An isolated host cell genetically transformed with the nucleic acid molecule according to claim 2 .

5. A gene delivery system, comprising the nucleic acid molecule according to claim 2 .

6. A composition comprising the gene delivery system according to claim 5 .

7. A pharmaceutical composition, comprising the chimeric thrombin-cleavable derivative of claim 1 and a pharmaceutically acceptable excipient.

8. The pharmaceutical composition of claim 7 , which is a procoagulant medicinal product, wherein the chimeric thrombin-cleavable derivative is a chimeric factor X.

9. The pharmaceutical composition of claim 7 , which is a procoagulant medicinal product, wherein the serine protease derivative is a factor X derivative.

10. A chimeric thrombin-cleavable derivative of a seine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a modified native cleavage site for thrombin of the protein C, wherein the amino acids P 2 ′-P 3 ′ are represented by Ile-Asp, or the factor X, wherein the amino acids P 2 ′-P 3 ′ are represented by Val-Gly, and wherein the amino acid at position P 1 ′ of the protein C and/or the factor X is an alanine or a seine.

11. A serine protease derivative which is a protein C derivative obtained by a thrombin cleavage of the chimeric protein C derivative according to claim 10 .

12. A chimeric thrombin-cleavable derivative of a serine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a modified native cleavage site for thrombin of the protein C, wherein the amino acids P 1 ′ and P 3 ′ are represented by Leu and Asp, respectively, or the factor X, wherein the amino acids P 1 ′ and P 3 ′ are represented by Ile and Gly, respectively, and wherein the amino acid at position P 2 ′ of the protein C and/or the factor X is a phenylalanine.

13. A seine protease derivative which is a protein C derivative obtained by a thrombin cleavage of the chimeric protein C derivative according to claim 12 .

14. A serine protease derivative which is a factor X derivative obtained by a thrombin cleavage of the chimeric factor X derivative according to claim 12 .

15. A chimeric thrombin-cleavable derivative of a seine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a modified native cleavage site for thrombin of the protein C, wherein the amino acids P 1 ′-P 2 ′ are represented by Leu-Ile, or the factor X, wherein the amino acids P 1 ′-P 2 ′ are represented by Ile-Val, and wherein the amino acid at position P 3 ′ of the protein C and/or the factor X is a glycine.

16. A chimeric thrombin cleavable derivative of serine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a modified native cleavage site for thrombin of the protein C, wherein the amino acids P 3 ′ is Asp, or the factor X, wherein the amino acids P 3 ′ is Gly, and wherein the amino acid at position P 1 ′ of the protein C and/or the factor X is an alanine or a seine, and the amino acid at position P 2 ′ of the protein C and/or the factor X is a phenylalanine.

17. A seine protease derivative which is a protein C derivative obtained by a thrombin cleavage of the chimeric protein C derivative according to claim 16 .

18. A seine protease derivative which is a factor X derivative obtained by a thrombin cleavage of the chimeric factor X derivative according to claim 16 .

19. A chimeric thrombin cleavable derivative of seine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a modified native cleavage site for thrombin of the protein C, wherein the amino acids P 2 ′ is Ile, or the factor X, wherein the amino acids P 2 ′ is Val, and wherein the amino acid at position P 1 ′ of the protein C and/or the factor X is an alanine or a serine, and the amino acid at position P 3 ′ of the protein C and/or the factor X is a glycine.

20. A seine protease derivative which is a protein C derivative obtained by a thrombin cleavage of the chimeric protein C derivative according to claim 19 .

21. A chimeric thrombin cleavable derivative of serine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a modified native cleavage site for thrombin of the protein C, wherein the amino acids P 1 ′ is Leu, or the factor X, wherein the amino acids P 1 ′ is Ile, and wherein the amino acid at position P 2 ′ of the protein C and/or the factor X is phenylalanine, and the amino acid at position P 3 ′ of the protein C and/or the factor X is a glycine.

22. A seine protease derivative which is a protein C derivative obtained by a thrombin cleavage of a protein the chimeric C derivative according to claim 21 .

23. A chimeric thrombin cleavable derivative of seine protease zymogen selected from the group consisting of protein C and factor X, wherein the native activation peptide of said zymogen is replaced with fibrinopeptide A, or a portion thereof, said replacement generates a thrombin-cleavable sequence P 10 P 9 P 8 P 7 P 6 P 5 P 4 P 3 P 2 P 1 P 1 ′P 2 ′P 3 ′ (SEQ ID NO:32), comprising amino acids P 10 to P 1 of fibrinopeptide A (SEQ ID NO:2) and amino acids P 1 ′-P 2 ′-P 3 ′ of a modified native cleavage site for thrombin of the protein C or the factor X, wherein the amino acid at position P 1 ′ is an alanine or a serine, the amino acid at position P 2 ′ is a phenylalanine and the amino acid at position P 3 ′ is a glycine.

24. A serine protease derivative which is a protein C derivative obtained by a thrombin cleavage of a the chimeric protein C derivative according to claim 23 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2005
From: LE BONNIEC, BERNARD; MARQUE, PIERRE-EMMANUEL; LOUVAIN, VIRGINIE; CALMEL, CLAIRE; BIANCHINI, ELSA; AIACH, MARTINE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM)
Reel/Frame 016370/0138 →
Priority Claims (1)
FR 01 13492 · Oct 19, 2001 · national
Continuity (1)
Related Publication 20050202527A1 · Sep 15, 2005